These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9571304)

  • 1. Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability.
    Levy G
    Clin Pharmacokinet; 1998 Apr; 34(4):323-33. PubMed ID: 9571304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics.
    Chen ML
    Clin Pharmacokinet; 2006; 45(10):957-64. PubMed ID: 16984210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding clinical applications of population pharmacodynamic modelling.
    Minto C; Schnider T
    Br J Clin Pharmacol; 1998 Oct; 46(4):321-33. PubMed ID: 9803979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic variability: a daunting challenge in drug therapy.
    Lin JH
    Curr Drug Metab; 2007 Feb; 8(2):109-36. PubMed ID: 17305491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gender differences in pharmacokinetics and pharmacodynamics.
    Beierle I; Meibohm B; Derendorf H
    Int J Clin Pharmacol Ther; 1999 Nov; 37(11):529-47. PubMed ID: 10584975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.
    De Paepe P; Belpaire FM; Buylaert WA
    Clin Pharmacokinet; 2002; 41(14):1135-51. PubMed ID: 12405864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic analysis of sparse data from concentration- and effect-controlled clinical trials guided by a pilot study. An investigation by simulations.
    Fullerton T; Forrest A; Levy G
    J Pharm Sci; 1996 Jun; 85(6):600-7. PubMed ID: 8773956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics: current requirements and future perspectives from a regulatory point of view.
    Shah RR
    Xenobiotica; 1993 Nov; 23(11):1159-93. PubMed ID: 8310705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug therapy in childhood: what has been done and what has to be done?
    Bartels H
    Pediatr Pharmacol (New York); 1983; 3(3-4):131-43. PubMed ID: 6677868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
    Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
    Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials.
    Ebling WF; Levy G
    Ann Pharmacother; 1996 Jan; 30(1):12-9. PubMed ID: 8773159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pharmacodynamic variability on drug delivery(1).
    Levy G
    Adv Drug Deliv Rev; 1998 Sep; 33(3):201-206. PubMed ID: 10837660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol.
    Donnelly R; Macphee GJ
    Clin Pharmacokinet; 1991 Aug; 21(2):95-109. PubMed ID: 1884570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.
    Danhof M; de Jongh J; De Lange EC; Della Pasqua O; Ploeger BA; Voskuyl RA
    Annu Rev Pharmacol Toxicol; 2007; 47():357-400. PubMed ID: 17067280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.
    Gabrielsson J; Green AR
    J Pharmacol Exp Ther; 2009 Dec; 331(3):767-74. PubMed ID: 19779129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
    Eriksson UG; Mandema JW; Karlsson MO; Frison L; Gisleskog PO; Wählby U; Hamrén B; Gustafsson D; Eriksson BI
    Clin Pharmacokinet; 2003; 42(7):687-701. PubMed ID: 12844328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic-pharmacodynamic relationship.
    Baggot JD
    Ann Rech Vet; 1990; 21 Suppl 1():29S-40S. PubMed ID: 2080844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.